SK11202003A3 - Použitie tiolutín-dioxidu a jeho derivátov na prípravu liečiva, spôsob jeho prípravy pomocou mikroorganizmu a mikroorganizmus Nocardiopsis species ST 100692, DSM 13834 - Google Patents

Použitie tiolutín-dioxidu a jeho derivátov na prípravu liečiva, spôsob jeho prípravy pomocou mikroorganizmu a mikroorganizmus Nocardiopsis species ST 100692, DSM 13834 Download PDF

Info

Publication number: SK11202003A3
Authority: SK; Slovakia
Prior art keywords: formula; compound; dsm; thiolutin; microorganism
Prior art date: 2001-03-09

Application number

SK1120-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Claudia Eder

Michael Kurz

Joachim Wink

Original Assignee

Aventis Pharma Deutschland Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-09

Filing date

2002-02-23

Publication date

2004-02-03

2002-02-23 Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh

2004-02-03 Publication of SK11202003A3 publication Critical patent/SK11202003A3/sk

Links

MHMRAFONCSQAIA-UHFFFAOYSA-N thiolutin Chemical compound S1SC=C2N(C)C(=O)C(NC(=O)C)=C21 MHMRAFONCSQAIA-UHFFFAOYSA-N 0.000 title claims abstract description 78
LJRHSDGQWGPCCR-UHFFFAOYSA-N thiolutin Natural products S1SC=C2NC(=O)C(NC(=O)C)C21 LJRHSDGQWGPCCR-UHFFFAOYSA-N 0.000 title claims abstract description 39
238000000034 method Methods 0.000 title claims abstract description 23
244000005700 microbiome Species 0.000 title claims abstract description 12
239000003814 drug Substances 0.000 title claims abstract description 9
238000002360 preparation method Methods 0.000 title claims description 12
238000004519 manufacturing process Methods 0.000 title abstract description 10
208000015114 central nervous system disease Diseases 0.000 claims abstract description 6
150000001875 compounds Chemical class 0.000 claims description 47
150000003839 salts Chemical class 0.000 claims description 21
235000015097 nutrients Nutrition 0.000 claims description 16
125000002252 acyl group Chemical group 0.000 claims description 9
241000203622 Nocardiopsis Species 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 8
230000035772 mutation Effects 0.000 claims description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
239000001257 hydrogen Substances 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
241000994644 Diopsis Species 0.000 claims 1
150000001721 carbon Chemical group 0.000 claims 1
238000000855 fermentation Methods 0.000 abstract description 6
230000004151 fermentation Effects 0.000 abstract description 6
239000000243 solution Substances 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
239000002609 medium Substances 0.000 description 8
108090000812 Neurolysin Proteins 0.000 description 7
102100023072 Neurolysin, mitochondrial Human genes 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
239000000284 extract Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
240000008042 Zea mays Species 0.000 description 5
235000002017 Zea mays subsp mays Nutrition 0.000 description 5
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
235000013312 flour Nutrition 0.000 description 5
239000008103 glucose Substances 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
229920001817 Agar Polymers 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
235000010469 Glycine max Nutrition 0.000 description 4
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
235000010419 agar Nutrition 0.000 description 4
235000005822 corn Nutrition 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
244000068988 Glycine max Species 0.000 description 3
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000008272 agar Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000000651 prodrug Substances 0.000 description 3
229940002612 prodrug Drugs 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
239000011701 zinc Substances 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
-1 2,2-dimethylbutyl Chemical group 0.000 description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
102000050267 Neurotensin Human genes 0.000 description 2
101800001814 Neurotensin Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000012496 blank sample Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
150000001805 chlorine compounds Chemical class 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000012258 culturing Methods 0.000 description 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000013372 meat Nutrition 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 2
FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000011347 resin Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
239000012138 yeast extract Substances 0.000 description 2
125000006017 1-propenyl group Chemical group 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
125000005916 2-methylpentyl group Chemical group 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
125000005917 3-methylpentyl group Chemical group 0.000 description 1
125000006043 5-hexenyl group Chemical group 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
101000775660 Anarhichas lupus Type-3 ice-structuring protein 1.5 Proteins 0.000 description 1
101000775628 Anarhichas lupus Type-3 ice-structuring protein 1.9 Proteins 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
239000002028 Biomass Substances 0.000 description 1
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
101710128742 Cytochrome b6-f complex iron-sulfur subunit 2 Proteins 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108090000028 Neprilysin Proteins 0.000 description 1
102000003729 Neprilysin Human genes 0.000 description 1
101000643905 Nostoc sp. (strain PCC 7120 / SAG 25.82 / UTEX 2576) Cytochrome b6-f complex iron-sulfur subunit 3 Proteins 0.000 description 1
102100027069 Odontogenic ameloblast-associated protein Human genes 0.000 description 1
101710091533 Odontogenic ameloblast-associated protein Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
239000005643 Pelargonic acid Substances 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
101000775697 Pseudopleuronectes americanus Ice-structuring protein 3 Proteins 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
241000209140 Triticum Species 0.000 description 1
102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000005273 aeration Methods 0.000 description 1
238000010564 aerobic fermentation Methods 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
238000011953 bioanalysis Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229920001429 chelating resin Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000006704 dehydrohalogenation reaction Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000013100 final test Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
238000005187 foaming Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000011141 high resolution liquid chromatography Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
ZOCYQVNGROEVLU-UHFFFAOYSA-N isopentadecanoic acid Chemical compound CC(C)CCCCCCCCCCCC(O)=O ZOCYQVNGROEVLU-UHFFFAOYSA-N 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
MOUPNEIJQCETIW-UHFFFAOYSA-N lead chromate Chemical group [Pb+2].[O-][Cr]([O-])(=O)=O MOUPNEIJQCETIW-UHFFFAOYSA-N 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000009973 maize Nutrition 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
230000007721 medicinal effect Effects 0.000 description 1
239000000401 methanolic extract Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
229960002446 octanoic acid Drugs 0.000 description 1
DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
229940066779 peptones Drugs 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000013641 positive control Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000013587 production medium Substances 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000000746 purification Methods 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
238000012216 screening Methods 0.000 description 1
125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
241000894007 species Species 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
108010046845 tryptones Proteins 0.000 description 1
125000004417 unsaturated alkyl group Chemical group 0.000 description 1
229940005605 valeric acid Drugs 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

SK1120-2003A 2001-03-09 2002-02-23 Použitie tiolutín-dioxidu a jeho derivátov na prípravu liečiva, spôsob jeho prípravy pomocou mikroorganizmu a mikroorganizmus Nocardiopsis species ST 100692, DSM 13834 SK11202003A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01105959A EP1238668A1 (en)	2001-03-09	2001-03-09	Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of CNS disorders and a process for the preparation thereof
PCT/EP2002/001915 WO2002072089A2 (en)	2001-03-09	2002-02-23	Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of cns disorders and a process for the preparation thereof

Publications (1)

Publication Number	Publication Date
SK11202003A3 true SK11202003A3 (sk)	2004-02-03

Family

ID=8176735

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1120-2003A SK11202003A3 (sk)	2001-03-09	2002-02-23	Použitie tiolutín-dioxidu a jeho derivátov na prípravu liečiva, spôsob jeho prípravy pomocou mikroorganizmu a mikroorganizmus Nocardiopsis species ST 100692, DSM 13834

Country Status (24)

Country	Link
US (2)	US20020193418A1 (pl)
EP (2)	EP1238668A1 (pl)
JP (1)	JP2004521927A (pl)
KR (1)	KR20040025902A (pl)
CN (1)	CN1279906C (pl)
AT (1)	ATE333276T1 (pl)
AU (1)	AU2002250997B2 (pl)
BG (1)	BG108161A (pl)
BR (1)	BR0207884A (pl)
CA (1)	CA2439853A1 (pl)
CZ (1)	CZ20032427A3 (pl)
DE (1)	DE60213219D1 (pl)
EE (1)	EE200300430A (pl)
HR (1)	HRP20030714A2 (pl)
IL (1)	IL157792A0 (pl)
MX (1)	MXPA03007551A (pl)
NO (1)	NO20033964L (pl)
NZ (1)	NZ528071A (pl)
PL (1)	PL363374A1 (pl)
RU (1)	RU2003129889A (pl)
SK (1)	SK11202003A3 (pl)
WO (1)	WO2002072089A2 (pl)
YU (1)	YU68403A (pl)
ZA (1)	ZA200306474B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108371661B (zh) *	2018-01-19	2019-03-19	中国人民解放军军事科学院军事医学研究院	硫藤黄菌素在抑制nlrp3炎症小体活化中的应用
CN113209088B (zh) *	2021-03-11	2022-03-22	中国人民解放军军事科学院军事医学研究院	硫藤黄菌素在保护非酒精性脂肪性肝炎中的应用
CN115261422B (zh) *	2022-06-30	2024-07-16	塔里木大学	一种新物种来源硫藤黄菌素的制备方法及应用
CN118477070B (zh) *	2024-05-15	2025-09-09	中国人民解放军军事科学院军事医学研究院	硫藤黄菌素在预防和/或治疗放射性肺损伤中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996032396A1 (en) *	1995-04-11	1996-10-17	John Malcolm Webster	Xenorxides with antibacterial and antimycotic properties
CA2212237A1 (en) *	1997-09-05	1999-03-05	John M. Webster	Novel antineoplastic agents

2001
- 2001-03-09 EP EP01105959A patent/EP1238668A1/en not_active Withdrawn
2002
- 2002-02-23 HR HR20030714A patent/HRP20030714A2/xx not_active Application Discontinuation
- 2002-02-23 YU YU68403A patent/YU68403A/sh unknown
- 2002-02-23 KR KR10-2003-7011817A patent/KR20040025902A/ko not_active Withdrawn
- 2002-02-23 AT AT02719902T patent/ATE333276T1/de not_active IP Right Cessation
- 2002-02-23 SK SK1120-2003A patent/SK11202003A3/sk unknown
- 2002-02-23 PL PL02363374A patent/PL363374A1/pl unknown
- 2002-02-23 NZ NZ528071A patent/NZ528071A/en unknown
- 2002-02-23 EP EP02719902A patent/EP1372640B1/en not_active Expired - Lifetime
- 2002-02-23 JP JP2002571048A patent/JP2004521927A/ja not_active Abandoned
- 2002-02-23 RU RU2003129889/15A patent/RU2003129889A/ru not_active Application Discontinuation
- 2002-02-23 CA CA002439853A patent/CA2439853A1/en not_active Abandoned
- 2002-02-23 MX MXPA03007551A patent/MXPA03007551A/es unknown
- 2002-02-23 BR BR0207884-8A patent/BR0207884A/pt not_active IP Right Cessation
- 2002-02-23 AU AU2002250997A patent/AU2002250997B2/en not_active Ceased
- 2002-02-23 CN CNB028079493A patent/CN1279906C/zh not_active Expired - Fee Related
- 2002-02-23 EE EEP200300430A patent/EE200300430A/xx unknown
- 2002-02-23 CZ CZ20032427A patent/CZ20032427A3/cs unknown
- 2002-02-23 DE DE60213219T patent/DE60213219D1/de not_active Expired - Lifetime
- 2002-02-23 IL IL15779202A patent/IL157792A0/xx unknown
- 2002-02-23 WO PCT/EP2002/001915 patent/WO2002072089A2/en not_active Ceased
- 2002-03-08 US US10/092,882 patent/US20020193418A1/en not_active Abandoned
2003
- 2003-08-20 ZA ZA200306474A patent/ZA200306474B/en unknown
- 2003-09-08 NO NO20033964A patent/NO20033964L/no unknown
- 2003-09-08 BG BG108161A patent/BG108161A/xx unknown
2004
- 2004-10-26 US US10/973,309 patent/US20050059725A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20033964D0 (no)	2003-09-08
AU2002250997B2 (en)	2006-03-09
EP1372640B1 (en)	2006-07-19
YU68403A (sh)	2006-08-17
WO2002072089A2 (en)	2002-09-19
RU2003129889A (ru)	2005-03-10
CA2439853A1 (en)	2002-09-19
EP1372640A2 (en)	2004-01-02
IL157792A0 (en)	2004-03-28
MXPA03007551A (es)	2003-12-04
US20050059725A1 (en)	2005-03-17
PL363374A1 (pl)	2004-11-15
CN1501800A (zh)	2004-06-02
EE200300430A (et)	2003-12-15
JP2004521927A (ja)	2004-07-22
BG108161A (en)	2004-09-30
HRP20030714A2 (en)	2005-04-30
EP1238668A1 (en)	2002-09-11
US20020193418A1 (en)	2002-12-19
ATE333276T1 (de)	2006-08-15
CN1279906C (zh)	2006-10-18
BR0207884A (pt)	2004-07-27
DE60213219D1 (de)	2006-08-31
NO20033964L (no)	2003-09-08
CZ20032427A3 (cs)	2004-01-14
NZ528071A (en)	2005-02-25
WO2002072089A3 (en)	2002-11-14
ZA200306474B (en)	2004-04-29
KR20040025902A (ko)	2004-03-26

Legal Events

Date	Code	Title	Description
2010-05-07	FB9A	Suspension of patent application procedure

Publication	Publication Date	Title
AU784902B2 (en)	2006-07-20	Percyquinnin, a process for its production and its use as a pharmaceutical
CZ261493A3 (en)	1994-07-13	Pharmacologically active compounds, process of their preparation and pharmaceutical preparations in which they are comprised
JP2010531823A (ja)	2010-09-30	マクロラクトン誘導体
DK170892B1 (da)	1996-03-04	14-Oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12]tetra-deca-2,4,6-trien-forbindelser, fremgangsmåde til fremstilling heraf, farmaceutiske præparater der indeholder forbindelserne samt anvendelse af forbindelserne til fremstilling af lægemidler og en kultur af mikroorganismen Streptomyces sandaensis
SK11202003A3 (sk)	2004-02-03	Použitie tiolutín-dioxidu a jeho derivátov na prípravu liečiva, spôsob jeho prípravy pomocou mikroorganizmu a mikroorganizmus Nocardiopsis species ST 100692, DSM 13834
JP4758905B2 (ja)	2011-08-31	２−フェニル−ベンゾフラン誘導体、その製造方法及びその使用
US20190127313A1 (en)	2019-05-02	Antimicrobial agents
JP4769190B2 (ja)	2011-09-07	ベンガミド誘導体、それらの製造方法、および癌処置のためのそれらの使用
JP5619001B2 (ja)	2014-11-05	ストレプトスピロール誘導体
AU2002250997A1 (en)	2003-03-20	Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of CNS disorders and a process for the preparation thereof
MXPA02000173A (es)	2002-07-30	Nuevos alcaloides de indolocarbazola de un actinomiceto marino.
SK11182003A3 (sk)	2004-02-03	Deriváty caloporozidu, liečivá s ich obsahom, spôsob prípravy týchto látok pomocou mikroorganizmu a tento mikroorganizmus
US6962943B2 (en)	2005-11-08	Gabusectin derivatives, processes for preparing them and their use
US7148254B2 (en)	2006-12-12	2-Phenylbenzofuran derivatives, a process for preparing them, and their use
HK1061656A (en)	2004-09-30	Use of thiolutin dioxide and its derivatives in the manufacture of a medicament, and a process for the preparation thereof
SK286776B6 (sk)	2009-05-07	Amycomycin, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje
HK1125410A (en)	2009-08-07	Bengamide derivatives, method for the production thereof and use thereof for the treatment of cancer
HK1098131B (en)	2009-03-20	Bengamide derivatives, method for the production thereof and use thereof for the treatment of cancer
JPH1017527A (ja)	1998-01-20	抗菌性物質ｂｅ−３９５８９類及びその製造法
CA2467251A1 (en)	2003-05-30	Gabusectin derivatives, method for the production thereof and use of the same